Treatment of two cases with refractory, metastatic intermediate-risk neuroblastoma with isotretenoin alone or observation

Pediatric Blood and Cancer

Volumn 61, Issue 6, 2014, Pages 1104-1106

  Pinto, Navin ^a   Cipkala, Douglas A ^b   Ladd, Patricia E ^b   Pu, Yonglin ^a   Cohn, Susan L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Peyton Manning Children's Hospital   (United States)

Author keywords

Intermediate risk neuroblastoma; Neuroblastoma; Refractory disease

Indexed keywords

CATECHOLAMINE; CYCLOPHOSPHAMIDE; HOMOVANILLIC ACID; ISOTRETINOIN; TOPOTECAN;

ARTICLE; BONE MARROW BIOPSY; BONE MARROW DISEASE; CANCER CHEMOTHERAPY; CANCER STAGING; CASE REPORT; CHROMOSOME 11Q; CHROMOSOME 1P; CHROMOSOME LOSS; CYTOTOXICITY; ECCHYMOSIS; FEMALE; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; INFANT; LYMPHADENOPATHY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUROBLASTOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROPERITONEAL CANCER; TREATMENT RESPONSE; TUMOR GROWTH;

INTERMEDIATE-RISK NEUROBLASTOMA; NEUROBLASTOMA; REFRACTORY DISEASE;

ABDOMINAL NEOPLASMS; ADRENAL GLAND NEOPLASMS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; HUMANS; INFANT; ISOTRETINOIN; LYMPHATIC METASTASIS; MALE; NEUROBLASTOMA; ORBITAL NEOPLASMS; PROGNOSIS; RETROPERITONEAL NEOPLASMS; RISK; SALVAGE THERAPY; THORACIC NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; WATCHFUL WAITING;

EID: 84901722744     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24889     Document Type: Article

References (12)

1. Maris JM, Hogarty MD, Bagatell R. et al. Neuroblastoma. Lancet 2007; 369:2106-2120.
2. Baker DL, Schmidt ML, Cohn SL. et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med 2010; 363:1313-1323.
3. Park JR, Scott JR, Stewart CF. et al. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study. J Clin Oncol 2011; 29:4351-4357.
4. Look AT, Hayes FA, Shuster JJ. et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 1991; 9:581-591.
5. Bowman LC, Castleberry RP, Cantor A. et al. Genetic staging of unresectable or metastatic neuroblastoma in infants: A Pediatric Oncology Group study. J Natl Cancer Inst 1997; 89:373-380.
6. Caron H, van Sluis P, de Kraker J. et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 1996; 334:225-230.
7. Attiyeh EF, London WB, Mosse YP. et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005; 353:2243-2253.
8. Shimada H, Ambros IM, Dehner LP. et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999; 86:364-372.
9. Schmidt ML, Lukens JN, Seeger RC. et al. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study. J Clin Oncol 2000; 18:1260-1268.
10. Bagatell R, Rumcheva P, London WB. et al. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy. J Clin Oncol 2005; 23:8819-8827.
11. London WB, Frantz CN, Campbell LA. et al. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: A Children's Oncology Group study. J Clin Oncol 2010; 28:3808-3815.
12. Matthay KK, Villablanca JG, Seeger RC. et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999; 341:1165-1173.